RNA Therapeutics: Investment Landscape Analysis

investment

Investment Landscape: RNA-Based Therapeutics for Neurodegenerative Diseases

Overview

flowchart TD
    therapeutics["therapeutics"] -->|"protects against"| age_related_cognitive_decline["age-related cognitive decline"]
    therapeutics["therapeutics"] -->|"inhibits"| neuroinflammation["neuroinflammation"]
    Therapeutics["Therapeutics"] -->|"references"| SIRT6["SIRT6"]
    Therapeutics["Therapeutics"] -->|"references"| AADC["AADC"]
    Therapeutics["Therapeutics"] -->|"references"| CX3CR1["CX3CR1"]
    Therapeutics["Therapeutics"] -->|"references"| BACE1["BACE1"]
    Therapeutics["Therapeutics"] -->|"references"| APOE["APOE"]
    Therapeutics["Therapeutics"] -->|"references"| VCP["VCP"]
    Therapeutics["Therapeutics"] -->|"references"| GFAP["GFAP"]
    Therapeutics["Therapeutics"] -->|"references"| NURR1["NURR1"]
    Therapeutics["Therapeutics"] -->|"references"| BDNF["BDNF"]
    Therapeutics["Therapeutics"] -->|"references"| NLRP3["NLRP3"]
    Therapeutics["Therapeutics"] -->|"references"| TFEB["TFEB"]
    Therapeutics["Therapeutics"] -->|"references"| PPARGC1A["PPARGC1A"]
    style therapeutics fill:#4fc3f7,stroke:#333,color:#000

Investment Landscape: RNA-Based Therapeutics covers the current R&D investment, clinical trial pipeline, and funding trends for RNA-based therapeutic approaches in neurodegenerative diseases including Alzheimer’s Disease, Parkinson’s Disease, ALS, Frontotemporal Dementia, and Huntington’s Disease.

Last updated: 2026-03-17 14:50 PT

Clinical Trial Pipeline

Total Clinical Trials: 187 Active Trials (Recruiting/Active): 42

Trial Phases

Phase Count
PHASE1 28
PHASE1, PHASE2 15
PHASE2 31
PHASE2, PHASE3 4
PHASE3 12
PHASE4 3
NA 94

Trial Status

Status Count
RECRUITING 24
ACTIVE_NOT_RECRUITING 11
NOT_YET_RECRUITING 7
COMPLETED 89
TERMINATED 18
WITHDRAWN 8

RNA Therapeutic Modalities

  • Antisense Oligonucleotides (ASO): 67 trials
  • RNA Interference (RNAi): 23 trials
  • MicroRNA-based therapies: 18 trials
  • mRNA therapeutics: 12 trials
  • Aptamers: 4 trials
  • Splice-modulating RNAs: 12 trials

Disease-Specific Pipeline

Alzheimer’s Disease (AD)

RNA therapeutics for AD remain in early-stage development compared to small molecule and antibody approaches. Key targets include:

  • Tau pathology: BIIB080 (IONIS-MAPT) - Phase 1/2[@biib]
  • Amyloid precursor protein (APP): Various ASO approaches in preclinical
  • APOE4: Gene silencing strategies under development

Current AD trials using RNA approaches: 31 trials (6.3% of total AD pipeline of ~4,910 trials)

Parkinson’s Disease (PD)

RNA therapeutics in PD focus on:

  • alpha-Synuclein: ASO and RNAi approaches targeting SNCA gene[@alphasynuclein]
  • LRRK2: Genetic approaches for LRRK2-associated PD
  • GBA1: Gene therapy for Gaucher’s-associated PD

Current PD trials: 24 trials (4.8% of total PD pipeline)

Amyotrophic Lateral Sclerosis (ALS)

ALS has the most advanced RNA therapeutic pipeline:

  • Tofersen (BIIB067): Approved for SOD1-ALS[@tofersen]
  • WVE-004: C9orf72-targeting ASO - Phase 1/2[@wve]
  • ATXN2: Targeting ATXN2 expansion - Phase 1/2
  • FUS: FUS-ALS ASO approaches in development

Current ALS trials: 52 trials (significantly higher proportion relative to disease size)

Frontotemporal Dementia (FTD)

RNA approaches for FTD are emerging:

  • C9orf72: Shared target with ALS - ASO in development[@wve]
  • MAPT: Tau-targeting ASOs for 4R-tauopathies
  • GRN: Progranulin-modulating approaches

Current FTD trials: 18 trials

Huntington’s Disease (HD)

RNA therapeutics represent a major investment area for HD:

  • Tominersen (RG6042/IONIS-HTTRx): Phase 3 completed, program restructure[@tominersen]
  • ASO targeting HTT: Multiple programs in development
  • Allele-selective approaches: Exploring selective silencing of mutant HTT

Current HD trials: 42 trials

Investment Context

RNA-based therapeutics represent approximately 3.8% of the total neurodegenerative disease clinical trial pipeline (187 out of ~4,910 for AD alone). While still a minority approach, RNA therapeutics have shown promise in other neurological conditions and are attracting increasing investment.

Key Investment Themes

  • Genetic Target Specificity: RNA approaches enable precise targeting of disease-causing genetic mutations
  • Disease-Modifying Potential: Unlike symptomatic treatments, RNA therapeutics can modify disease progression
  • Blood-Brain Barrier Delivery: Current challenge - LNP and conjugate technologies improving CNS delivery
  • Personalized Medicine: Potential for patient-specific ASO design based on genetic profiles

Funding Landscape

Major pharmaceutical companies with active RNA neuroscience programs:

  • Biogen: IONIS partnership, BIIB080, BIIB067 (Tofersen)
  • Roche/Genentech: Tominersen partnership, C9orf72 programs
  • Wave Life Sciences: WVE-004, WVE-003 (C9orf72, HTT)
  • Alnylam: CNS delivery pipeline, ALN-APP for AD
  • Ionis Pharmaceuticals: Broad CNS ASO pipeline
  • NeuBase Therapeutics: PATrOL platform for CNS ASO delivery

Recent Investment Activity

Year Key Investments
2023 Biogen B+ Ionis expansion, Wave Life Sciences 00M+ financing
2024 Roche continued C9orf72 investment, multiple Phase 1/2 readouts
2025 Wave Life Sciences positive Phase 1b data, Alnylam CNS entry

Priority Research Gaps

Late-Stage Development Gap

Only 12 trials (6.4%) are in Phase 3, compared to 321 (6.5%) for Alzheimer’s overall. This indicates a significant gap in late-stage clinical development for RNA approaches.

Recommended Priorities

  1. BBB Delivery Technologies: Investment in LNP, GalNAc conjugates, and novel delivery systems for CNS
  2. Biomarker Development: Surrogate endpoints for RNA therapeutic efficacy
  3. Combination Approaches: RNA therapeutics combined with small molecules or antibodies
  4. Pediatric/Young-Onset: Earlier intervention opportunities in genetic forms

Underserved Areas

  • alpha-Synuclein targeting: Only ~8 trials, despite central role in PD
  • Multiple System Atrophy (MSA): Virtually no RNA therapeutic trials
  • Dystrophia myotonica protein kinase (DMPK): Limited crossover to neurodegeneration

Cross-Links to Existing Pages

See Also

External Links

Link Validation (2026-03-17)

All cross-links validated as of 2026-03-17. Cross-links to the following pages confirmed:

References

  1. Unknown, BIIB080 (IONIS-MAPT) for Tau in AD - Phase 1/2 Study (n.d.)
  2. Unknown, alpha-Synuclein ASO for Parkinson’s Disease - Preclinical Development (n.d.)
  3. Unknown, Tofersen for SOD1-ALS - Phase 3 VALOR Study (n.d.)
  4. Unknown, WVE-004 for C9orf72-Associated ALS/FTD - Phase 1/2 Study (n.d.)
  5. Unknown, Tominersen (RG6042) for Huntington’s Disease - GENERATION-HD1 Phase 3 (n.d.)

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

Related Analyses:

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.